Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC

Introduction: Estrogen receptors (ER) (ERα, ERβ) and aromatase (key enzyme for estrogen synthesis) are expressed in most human NSCLCs. High intratumoral estrogen levels and elevated aromatase expression in NSCLC predict poor outcome. This open-label, phase 1b, single-center study evaluated the safet...

Full description

Bibliographic Details
Main Authors: Patricia A. Young, MD, Diana C. Márquez-Garbán, MD, Zorawar Singh Noor, MD, Neda Moatamed, MD, David Elashoff, PhD, Tristan Grogan, PhD, Tahmineh Romero, PhD, Hironobu Sasano, MD, PhD, Ryoko Saito, MD, PhD, Rebecca Rausch, PhD, Nalo Hamilton, PhD, Steven M. Dubinett, MD, Edward B. Garon, MD, Richard J. Pietras, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:JTO Clinical and Research Reports
Subjects:
Aromatase
Exemestane
Lung cancer
Estrogen
Estrogen receptor
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000096

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000096

Similar Items